Tilray Inc TRLY shares are trading higher by 16.25% to $2.79 Wednesday afternoon amid strength in the broader cannabis sector. Shares of cannabis stocks are trading higher following a report suggesting the Department of Health and Human Services (HHS) has called for moving marijuana to a lower-risk drug category.
According to a letter dated August 29 seen by Bloomberg News, a high-ranking official from the Department of Health and Human Services has written to DEA Administrator Anne Milgram, urging the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act.
This shift reflects a significant change, as Schedule I substances include highly abused drugs like heroin.
The recommendation is informed by an FDA evaluation of marijuana's classification. The Controlled Substances Act categorizes substances based on medical usage, abuse potential and safety.
These shifting conditions facing the cannabis industry will be discussed at the Benzinga Cannabis Capital Conference so you won't want to miss out. Join us in Chicago this September 27-28.
Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
According to data from Benzinga Pro, Tilray has a 52-week high of $5.12 and a 52-week low of $1.50.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.